These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

591 related articles for article (PubMed ID: 20347337)

  • 1. Implantable cardioverter-defibrillator shocks in patients with a left ventricular assist device.
    Ambardekar AV; Allen LA; Lindenfeld J; Lowery CM; Cannon AP; Cleveland JC; Brieke A; Sauer WH
    J Heart Lung Transplant; 2010 Jul; 29(7):771-6. PubMed ID: 20347337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistent atrial fibrillation is associated with appropriate shocks and heart failure in patients with left ventricular dysfunction treated with an implantable cardioverter defibrillator.
    Rienstra M; Smit MD; Nieuwland W; Tan ES; Wiesfeld AC; Anthonio RL; Van den Berg MP; Van Veldhuisen DJ; Van Gelder IC
    Am Heart J; 2007 Jan; 153(1):120-6. PubMed ID: 17174649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of implantable cardioverter-defibrillators in patients with continuous flow left ventricular assist devices.
    Enriquez AD; Calenda B; Miller MA; Anyanwu AC; Pinney SP
    Circ Arrhythm Electrophysiol; 2013 Aug; 6(4):668-74. PubMed ID: 23873139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of age and medical comorbidity on the effectiveness of implantable cardioverter-defibrillators for primary prevention.
    Chan PS; Nallamothu BK; Spertus JA; Masoudi FA; Bartone C; Kereiakes DJ; Chow T
    Circ Cardiovasc Qual Outcomes; 2009 Jan; 2(1):16-24. PubMed ID: 20031808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Left ventricular mechanical assist devices and cardiac device interactions: an observational case series.
    Foo D; Walker BD; Kuchar DL; Thorburn CW; Tay A; Hayward CS; Macdonald P; Keogh A; Kotlyar E; Spratt P; Jansz P
    Pacing Clin Electrophysiol; 2009 Jul; 32(7):879-87. PubMed ID: 19572863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy.
    Lin G; Nishimura RA; Gersh BJ; Phil D; Ommen SR; Ackerman MJ; Brady PA
    Heart; 2009 May; 95(9):709-14. PubMed ID: 19282314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous use of implantable cardioverter-defibrillators and left ventricular assist devices in patients with severe heart failure.
    Kühne M; Sakumura M; Reich SS; Sarrazin JF; Wells D; Chalfoun N; Crawford T; Boonyapisit W; Horwood L; Chugh A; Good E; Jongnarangsin K; Bogun F; Oral H; Morady F; Pagani F; Pelosi F
    Am J Cardiol; 2010 Feb; 105(3):378-82. PubMed ID: 20102952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of implantable cardioverter-defibrillators in patients with ischemic heart disease and left ventricular dysfunction.
    Chan PS; Chow T; Kereiakes D; Schloss EJ; Waller T; Eagle K; Hayward RA; Vijan S
    Arch Intern Med; 2006 Nov; 166(20):2228-33. PubMed ID: 17101941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Left ventricular ejection fraction and absence of ACE inhibitor/angiotensin II receptor blocker predicts appropriate defibrillator therapy in the primary prevention population.
    Obeyesekere MN; Chan W; Stub D; Prabhu S; Teo EP; Toogood G; Mariani J; Broughton A; Kistler PM
    Pacing Clin Electrophysiol; 2010 Jun; 33(6):696-704. PubMed ID: 20059719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infarct tissue heterogeneity assessed with contrast-enhanced MRI predicts spontaneous ventricular arrhythmia in patients with ischemic cardiomyopathy and implantable cardioverter-defibrillator.
    Roes SD; Borleffs CJ; van der Geest RJ; Westenberg JJ; Marsan NA; Kaandorp TA; Reiber JH; Zeppenfeld K; Lamb HJ; de Roos A; Schalij MJ; Bax JJ
    Circ Cardiovasc Imaging; 2009 May; 2(3):183-90. PubMed ID: 19808591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heart failure and the risk of shocks in patients with implantable cardioverter defibrillators: results from the Triggers Of Ventricular Arrhythmias (TOVA) study.
    Whang W; Mittleman MA; Rich DQ; Wang PJ; Ruskin JN; Tofler GH; Muller JE; Albert CM;
    Circulation; 2004 Mar; 109(11):1386-91. PubMed ID: 14993132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact.
    Daubert JP; Zareba W; Cannom DS; McNitt S; Rosero SZ; Wang P; Schuger C; Steinberg JS; Higgins SL; Wilber DJ; Klein H; Andrews ML; Hall WJ; Moss AJ;
    J Am Coll Cardiol; 2008 Apr; 51(14):1357-65. PubMed ID: 18387436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of left ventricular assist device placement on preexisting implantable cardioverter-defibrillator leads.
    Ambardekar AV; Lowery CM; Allen LA; Cannon AP; Cleveland JC; Lindenfeld J; Brieke A; Sauer WH
    J Card Fail; 2010 Apr; 16(4):327-31. PubMed ID: 20350700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ventricular proarrhythmic effects of atrial fibrillation are modulated by depolarization and repolarization anomalies in patients with left ventricular dysfunction.
    Lemola K; Khan R; Nattel S; Talajic M; Roy D; Guerra PG; Lemola S; Dubuc M; Thibault B; Macle L; Khairy P
    Pacing Clin Electrophysiol; 2009 Jan; 32(1):99-105. PubMed ID: 19140919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atrial fibrillation predicts appropriate shocks in primary prevention implantable cardioverter-defibrillator patients.
    Smit MD; Van Dessel PF; Rienstra M; Nieuwland W; Wiesfeld AC; Tan ES; Anthonio RL; Van Veldhuisen DJ; Van Gelder IC
    Europace; 2006 Aug; 8(8):566-72. PubMed ID: 16864611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of elapsed time from coronary revascularization to implantation of a cardioverter defibrillator on long-term survival in the MADIT-II trial.
    Barsheshet A; Goldenberg I; Moss AJ; Huang DT; Zareba W; McNitt S; Klein HU; Guetta V
    J Cardiovasc Electrophysiol; 2011 Nov; 22(11):1237-42. PubMed ID: 21615813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implantable cardioverter defibrillator therapy in adults with congenital heart disease: who is at risk of shocks?
    Koyak Z; de Groot JR; Van Gelder IC; Bouma BJ; van Dessel PF; Budts W; van Erven L; van Dijk AP; Wilde AA; Pieper PG; Sieswerda GT; Mulder BJ
    Circ Arrhythm Electrophysiol; 2012 Feb; 5(1):101-10. PubMed ID: 22095638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for appropriate cardioverter-defibrillator shocks, inappropriate cardioverter-defibrillator shocks, and time to mortality in 549 patients with heart failure.
    Desai H; Aronow WS; Ahn C; Gandhi K; Hussain S; Lai HM; Sharma M; Frishman WH; Cohen M; Sorbera C
    Am J Cardiol; 2010 May; 105(9):1336-8. PubMed ID: 20403488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mortality and appropriate and inappropriate therapy in patients with ischaemic heart disease and implanted cardioverter-defibrillators for primary prevention: data from the Danish ICD Register.
    Weeke P; Johansen JB; Jørgensen OD; Nielsen JC; Møller M; Videbæk R; Højgaard MV; Riahi S; Jacobsen PK
    Europace; 2013 Aug; 15(8):1150-7. PubMed ID: 23407630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic polymorphisms of the adrenergic system and implantable cardioverter-defibrillator therapies in patients with heart failure.
    Chemello D; Rohde LE; Santos KG; Silvello D; Goldraich L; Pimentel M; Rosa PR; Zimerman L; Clausell N
    Europace; 2010 May; 12(5):686-91. PubMed ID: 20185488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.